News | Heart Failure | April 15, 2016

Heart Failure Patients Experience Improved Outcomes Following Investigational Stem Cell Treatment

Cedars-Sinai Heart Institute physician presents stem cell therapy research at American College of Cardiology Scientific Sessions

April 15, 2016 — An investigational stem cell therapy derived from patients’ own blood marrow significantly improved outcomes in patients with severe heart failure, according to a study from the Cedars-Sinai Heart Institute.
The research was presented today as a late-breaking clinical trial at the American College of Cardiology (ACC) 2016 meeting. 

“This is an important step forward for heart patients in particular and for stem cell medicine in general,” said Timothy D. Henry, M.D., director of the cardiology division at the Cedars-Sinai Heart Institute, and one of the study’s lead authors. “The results indicate that stem cells could be ushering in a bright new era in heart failure treatments.” 

Results from the trial are published today online by peer-reviewed medical journal The Lancet. Henry is a lead author along with Amit N. Patel, M.D., MS, of the University of Utah. Cedars-Sinai also was one of the lead enrollers in the study. 

Called ixmyelocel-T, the stem cell treatment developed by pharmaceutical company Vericel is made from a patient’s own bone marrow. A sample of marrow is extracted from the patient and sent to a laboratory, where it undergoes a two-week process to rapidly multiply the number of stem cells and enhance their quality. The stem cell-rich marrow is then infused into the patient’s heart muscle during a minimally invasive, catheter-based procedure. 

“Our intent is to increase the number of functioning cells in the heart muscle, which, in turn, strengthen the heart and result in alleviating or slowing the advance of severe heart failure,” Henry said. 

In the Phase II study, physicians followed 109 patients over a 12-month period. All were diagnosed with ischemic cardiomyopathy, a type of heart failure that usually results from a heart attack or coronary artery disease. The 58 patients who received the stem cell therapy showed a 37 percent lower rate of deaths, hospitalizations and worsening symptoms compared to 51 patients who received a placebo. 

Results include: 
• Of patients who received stem cells, 3.4 percent died compared to 13.7 percent of placebo patients who died. 
• 37.9 percent of those who received stem cells were hospitalized with cardiovascular issues during the study. In comparison, 49 percent of patients who received the placebo were hospitalized during the study. 

The Cedars-Sinai Heart Institute has a deep history of developing stem cell treatments for heart patients. In 2009, Eduardo Marbán, M.D., PhD, director of the Heart Institute, led a team that completed the world's first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient's heart in an effort to repair and regrow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the investigational stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle after a heart attack. 

Since that first infusion, physicians in the Heart Institute have commenced multiple stem cell trials for a variety of heart patients. They also inaugurated a regenerative medicine clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies throughout the United States.

“Our focus is on finding each of our patients the most advanced treatment for their disease,” Marbán said. “Stem cells offer us an opportunity to improve cardiac care, expand treatment options and transform the future of heart medicine.” 


Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init